Lupin has informed that the company has enclosed a Press Release on 3rd April 2020 as regards receipt of the Establishment Inspection Report from the US FDA for the Company’s Aurangabad, India facility. The inspection for the facility was carried out by the US FDA between February 10, 2020 and February 14, 2020 and concluded with no observations. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE
